Estimated change (95% CI) versus baseline at | p-values | ||||
---|---|---|---|---|---|
Groups | 4 months | 8 months, | 12 months | P1 | P2 |
MMSE | |||||
Drug groups | |||||
Placebo | −0.402 (−0.988, 0.185) | −0.015 (−0.584, 0.553) | −0.335 (−1.046, 0.375) | 0.208 | 0.284 |
Donepezil | 0.145 (−0.440, 0.730) | 0.411 (−0.166, 0.988) | −0.470 (−1.181, 0.241) | ||
Municipality groups | |||||
Standard care | 0.198 (−0.429, 0.826) | 0.790 ( 0.190, 1.389) | 0.156 (−0.588, 0.901) | 0.017 | 0.508 |
Stimulation | −0.380 (−0.933, 0.172) | −0.272 (−0.807, 0.262) | −0.841 (−1.510, -0.172) | ||
Clock Drawing Test | |||||
Drug groups | |||||
Placebo | 0.103 (−0.081, 0.288) | 0.124 (−0.082, 0.330) | 0.134 (−0.079, 0.347) | 0.264 | 0.570 |
Donepezil | −0.016 (−0.200, 0.169) | −0.101 (−0.309, 0.107) | 0.031 (−0.183, 0.245) | ||
Municipality groups | |||||
Standard care | 0.120 (−0.076, 0.317) | 0.210 (−0.008, 0.428) | 0.234 ( 0.011, 0.456) | 0.071 | 0.257 |
Stimulation | −0.017 (−0.191, 0.158) | −0.144 (−0.339, 0.050) | −0.038 (−0.242, 0.165) | ||
ADAS-cog | |||||
Drug groups | |||||
Placebo | −0.383 (−1.412, 0.646) | −1.126 (−2.201, -0.051) | −0.492 (−1.635, 0.650) | 0.235 | 0.886 |
Donepezil | −1.027 (−2.053, -0.001) | −1.948 (−3.033, -0.862) | −1.510 (−2.661, -0.359) | ||
Municipality groups | |||||
Standard care | −1.515 (−2.597, -0.433) | −1.736 (−2.889, -0.582) | −1.619 (−2.830, -0.407) | 0.108 | 0.242 |
Stimulation | −0.069 (−1.030, 0.893) | −1.380 (−2.407, -0.352) | −0.493 (−1.590, 0.603) |